Skip to Content Skip to Search

Czech Republic

GSK employee listening to a podcast/web broadcast/Skype call

We focus on bringing innovative medicines, vaccines and over-the-counter products to as many Czech people as possible.

In the Czech Republic, we operate as a company with three divisions: Pharmaceuticals (prescription medicines), Vaccines (vaccination substances) and Consumer Healthcare (consumer healthcare products – in a range of categories, including pain relief, oral hygiene and skin care).

This year we placed highly in the Sodexo Employer of the Year ranking, just as we did in 2019. Once again, we took second place in the category of companies with up to 500 employees for the Prague region. We have thus held one of the top positions among employers in the Czech Republic over the long-term.

To achieve our goal – improving the quality of human life by enabling people to do more, feel better and live longer – it is essential to understand patient needs and diseases. Working with patient organisations is one way, which provides us with important information and helps us discover new medicines and vaccines. Patient organisations give patients support and information about how to live with their illness, represent them, defend their opinions and organise campaigns to make changes in areas that positively affect the lives of patients and their caregivers. We work with the organisations No foot no stress and Česká společnost AIDS pomoc, z.s. (Czech AIDS Help Society) on a regular basis.

In the Czech Republic, we regularly receive various socially responsible business and employee care awards. In 2019, we were recognised with a gold certificate in the Top responsible large corporation category in the Top responsible corporation competition organised by Business for Society, a platform of companies that aims to share and promote responsible and sustainable business principles in the Czech Republic.

Pharmaceuticals

GSK
Hvězdova 1734 / 2c
140 00 Praha 4
Czech Republic
Tel: +420 222 001 111
Fax: +420 222 001 444

Reporting of adverse effects

Email: cz.safety@gsk.com

Our Privacy Notice outlines how GSK handles the processing of personal information when dealing with your enquiry, complaint or adverse event report.

Pharmaceuticals/Vaccines
Reception
Tel: +420 222 001 111
E-mail: cz.info@gsk.com

Consumer Healthcare

GSK Consumer Healthcare
Hvězdova 1734 / 2c
140 00 Praha 4
Czech Republic
Tel: +420 222 001 111
Fax: +420 222 001 444

Reporting of adverse effects

Email: cz.safety@gsk.com

Our Privacy Notice outlines how GSK handles the processing of personal information when dealing with your enquiry, complaint or adverse event report.

Consumer Healthcare
Reception
Tel: +420 222 001 111
E-mail: cz.info@gsk.com

Billing information:

GlaxoSmithKline s.r.o.
Business ID No.: 48114057
Tax ID No.: CZ48114057

The company is registered in the Commercial Register administered by the Municipal Court in Prague, Section C, Insert 16558.

GlaxoSmithKline Consumer Healthcare 
Czech Republic s.r.o.
Business ID No.: 03655067
Tax ID No.: CZ03655067

The company is registered in the Commercial Register administered by the Municipal Court in Prague, Section C, Insert 235686.

Reporting of suspected adverse effects

The safety of active ingredients is just as important as their efficacy. Drug safety is monitored through pharmacovigilance. In practice, safety information assessment is primarily based on reporting of suspected adverse reactions by prescribing physicians.

Reported cases are collected in a global database and assessed in context with other data, and risks are analysed. The reported cases allow for detection of rare unexpected adverse reactions and quantitative assessment of expected adverse reactions. Safety alerts may have an impact on further use of a given medicinal product.

Please report any suspected adverse reactions to our products in writing to our mailbox: cz.safety@gsk.com

Our Privacy Notice outlines how GSK handles the processing of personal information when dealing with your enquiry, complaint or adverse event report.

Please also report to us drug administration in pregnancy, overdosage, addiction, medicinal product inefficacy, or unexpected positive effects, identified drug-drug interactions, off-label use, transfer of infectious agents by a medicine, suspected distribution of counterfeit items and/or other information related to safety.

Your information will be provided to the State Institute for Drug Control* pursuant to legislation.

Your reports serve as a source of information for more precise safety profiles of given medicinal products. 

*By clicking on the link you will leave the GSK Czech Republic website. GlaxoSmithKline s.r.o. bears no responsibility for the following content. 

Back to top

Customer relations

E-mail: michaela.m.spackova@gsk.com

Careers

Search for vacancies in the Czech Republic

Media Enquiries

Miriam Kejzlarová, PhD.
Communications Manager for the Czech Republic & Slovak Republic
miriam.m.kejzlarova@gsk.com

Transparent cooperation

Disclosure of payments made to healthcare professionals (HCPs) and healthcare organisations (HCOs) in the Czech Republic

In recent years GSK has challenged the traditional business model of pharmaceutical companies with industry-leading improvements to how we do business. Our improvements aim to meet society’s growing expectation that organisations and individuals should act transparently. This also includes relationships between our industry and healthcare professionals or healthcare organisations. They aim to ensure that all of these interactions are conducted with integrity and transparency. 

We fully support the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on the disclosure of individual payments from pharmaceutical companies to healthcare professionals and healthcare organisations.*

Under the code, and by 30 June 2018, EFPIA member companies across Europe, including GSK, pledged to disclose each fee paid in 2017 to a HCP or HCO in connection with prescription medicines by name (aggregate by exception only).

The disclosed data include, for example, HCP consultancy fees, meeting chair fees, sponsorship, and grants to HCOs. Payments to HCPs and HCOs for activities related to research and development have been disclosed as an aggregate number. The disclosures we made in June 2018 under the EFPIA code relate to 2017.

We believe these disclosures will help create a better understanding of how the pharmaceutical industry works with HCPs and HCOs. Through the measures that GSK has put in place we seek to increase confidence in, and understanding of, how and why we work with healthcare professions for the sustainable improvement of healthcare and in the best interest of patients. More information on our approach to the EFPIA code, our proposals for improvements to pharmaceutical industry practices, and the importance of our partnerships with HCPs and HCOs can be found below. 

View our payments for the Czech Republic here.*

*By clicking on the link you will leave the GSK Czech Republic website. GlaxoSmithKline s.r.o. bears no responsibility for the following content.

Back to top

Disclosure of support for patient organisations

Content Lab NP-CZ-NA-WCNT-200018, prepared in August 2020